Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Capital Expenditures (2016 - 2026)

Corvus Pharmaceuticals' Capital Expenditures history spans 9 years, with the latest figure at $91000.0 for Q1 2026.

  • Quarterly Capital Expenditures rose 152.78% to $91000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $229000.0 through Mar 2026, up 536.11% year-over-year, with the annual reading at $174000.0 for FY2025, N/A changed from the prior year.
  • Capital Expenditures came in at $91000.0 for Q1 2026, up from $25000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $265000.0 in Q3 2022 to a low of $25000.0 in Q4 2025.
  • The 4-year median for Capital Expenditures is $63500.0 (2025), against an average of $94000.0.
  • The largest YoY upside for Capital Expenditures was 152.78% in 2026 against a maximum downside of 152.78% in 2026.
  • Corvus Pharmaceuticals' Capital Expenditures stood at $265000.0 in 2022, then tumbled by 87.17% to $34000.0 in 2023, then decreased by 26.47% to $25000.0 in 2025, then soared by 264.0% to $91000.0 in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Capital Expenditures are $91000.0 (Q1 2026), $25000.0 (Q4 2025), and $113000.0 (Q2 2025).